JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab (NASDAQ:ZLAB – Get Free Report) had its target price lifted by equities research analysts at JPMorgan Chase & Co. from $36.00 to $37.00 in a research report issued on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 69.48% from the company’s previous close.

A number of other equities analysts have also issued reports on ZLAB. Wall Street Zen raised Zai Lab from a “sell” rating to a “hold” rating in a report on Saturday, September 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zai Lab in a research note on Tuesday, October 27th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zai Lab in a research report on Tuesday, October 6th. Finally, Citigroup increased their price target on Zai Lab from $44.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Zai Lab has an average rating of “Moderate Buy” and an average target price of $38.50.

Read Our Latest Stock Report on ZLAB

Zai Lab Trading Down 1.3%

Zai Lab stock traded down $0.28 during midday trading on Thursday, reaching $21.83. 356,782 shares of the stock traded hands, compared to its average volume of 896,562. The firm has a fifty day moving average price of $24.46 and a two-hundred day moving average price of $21.35. The firm has a market cap of $2.73 billion, a price-to-earnings ratio of -12.20 and a beta of 0.77. Zai Lab has a fifty-two week low of $15.96 and a fifty-two week high of $29.02.

Zai Lab (NASDAQ:ZLAB – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.18. The company had revenue of $108.21 million for the quarter, compared to analyst estimates of $107.90 million. Zai Lab had a negative net margin of 44.91% and a negative return on equity of 31.15%. Analysts anticipate that Zai Lab will post -2.19 earnings per share for the current year.

Insider Activity at Zai Lab

In related news, Director Richard Gaynor acquired 1,228 shares of the stock in a transaction that occurred on Tuesday, November 10th. The shares were acquired at an average price of $27.19 per share, for a total transaction of $33,389.32. Following the completion of the purchase, the director directly owned 81,965 shares of the company’s stock, valued at $2,228,628.35. The trade was a 1.52% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.88% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zai Lab

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZLAB. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Zai Lab in the third quarter valued at $62,000. Nykredit A S bought a new position in Zai Lab during the second quarter valued at about $79,000. China Universal Asset Management Co. Ltd. acquired a new position in Zai Lab during the third quarter worth about $211,000. HighVista Strategies LLC acquired a new position in Zai Lab during the third quarter worth about $609,000. Finally, WealthPlan Investment Management LLC bought a new stake in Zai Lab in the third quarter worth about $969,000. 41.65% of the stock is owned by institutional investors.

About Zai Lab

(Get Free Report)

Zai Lab is a biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases. Its research and development programs focus on oncology, immunology, neuroscience and infectious diseases. Founded in 2014 by biopharmaceutical executive Samantha Du, the company is headquartered in Shanghai and operates in China and the United States. It advances its own drug candidates and works with international partners to develop and bring therapies to market. Zai Lab’s portfolio includes medicines and development programs for cancers and other conditions, including therapies introduced through licensing and collaboration agreements.

Further Reading

Analyst Recommendations for Zai Lab (NASDAQ:ZLAB)

Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.